A detailed history of Avoro Capital Advisors LLC transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Avoro Capital Advisors LLC holds 11,111,111 shares of APLS stock, worth $378 Million. This represents 4.82% of its overall portfolio holdings.

Number of Shares
11,111,111
Previous 11,111,111 -0.0%
Holding current value
$378 Million
Previous $426 Million 24.82%
% of portfolio
4.82%
Previous 5.82%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023

BUY
$46.59 - $66.96 $22.6 Million - $32.5 Million
486,111 Added 4.58%
11,111,111 $733 Million
Q4 2022

Feb 14, 2023

BUY
$43.24 - $61.04 $21.6 Million - $30.5 Million
500,000 Added 4.94%
10,625,000 $549 Million
Q3 2022

Nov 14, 2022

BUY
$44.76 - $69.66 $14.3 Million - $22.3 Million
320,000 Added 3.26%
10,125,000 $692 Million
Q2 2022

Aug 15, 2022

BUY
$35.07 - $59.21 $12.4 Million - $21 Million
355,000 Added 3.76%
9,805,000 $443 Million
Q1 2022

May 16, 2022

BUY
$35.46 - $54.12 $31.7 Million - $48.4 Million
894,445 Added 10.45%
9,450,000 $480 Million
Q4 2021

Feb 14, 2022

BUY
$30.74 - $49.16 $109 Million - $175 Million
3,555,555 Added 71.11%
8,555,555 $405 Million
Q3 2021

Nov 15, 2021

BUY
$31.4 - $69.84 $125 Million - $279 Million
3,994,770 Added 397.4%
5,000,000 $165 Million
Q2 2021

Aug 16, 2021

BUY
$40.9 - $64.9 $213,907 - $339,427
5,230 Added 0.52%
1,005,230 $63.5 Million
Q1 2021

May 17, 2021

BUY
$40.8 - $57.39 $40.8 Million - $57.4 Million
1,000,000 New
1,000,000 $42.9 Million
Q2 2018

Aug 14, 2018

SELL
$19.63 - $30.0 $7.79 Million - $11.9 Million
-396,635 Closed
0 $0
Q4 2017

Feb 14, 2018

BUY
$12.71 - $21.7 $5.04 Million - $8.61 Million
396,635
396,635 $7.32 Million

Others Institutions Holding APLS

About Apellis Pharmaceuticals, Inc.


  • Ticker APLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 109,865,000
  • Market Cap $3.74B
  • Description
  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...
More about APLS
Track This Portfolio

Track Avoro Capital Advisors LLC Portfolio

Follow Avoro Capital Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Avoro Capital Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Avoro Capital Advisors LLC with notifications on news.